Loading
Lyra Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Waksal Harlan, was filed 13 Nov 2023.
Lyra Therapeutics, Inc.: what insiders have been doing
Lyra Therapeutics, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 23 October 2026, brought 17 filings signed by 4 insiders.
There is no open-market purchase to report; the filings show 14 sales worth €463k by 3 insiders. Biggest ticket of the year: €130k, sold by Perceptive Advisors LLC and made public on 10 November 2025.
Across the 279 companies tracked on its exchange, the median is 8 filings; at 17 filings, this issuer sits above that mark. Our records for Lyra Therapeutics, Inc. go back to 2020, with 31 purchases and 25 sales on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 398,000 USD and net income at -28.9 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
103
Thresholds
n/a
Buy Volume
€74M
31 ops. · all time
Sell Volume
€2M
25 ops. · all time
Who traded when
BuySalePerceptive Advisors LLC12 sales
Jason Cavalier2 sales
Maria Palasis2 sales
Since the insiders bought
- -93.1%Entry US$144.00 · Close at T+365 US$9.89
- -89.2%Entry US$150.00 · Close at T+365 US$16.25
- -89.2%Entry US$150.00 · Close at T+365 US$16.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.19
Analyst consensus
Income statement
RevenueUS$398k
EBITDA-US$29.1M-7310% margin
Net income-US$28.9M-7266.1% margin
Valuation
Beta0.50
Balance sheet & cash
Total debtUS$30.3M
Free Cash Flow-US$29M
Profitability & ownership
ROE-6595.0%
ROA-36.1%
% insiders0.6%
% institutions6.6%
Last declaration on 15 May 2026
Declarations103 total
640 shares0Common StockSEC:0001193125-26-227500:0
2,000 shares0Common StockSEC:0001193125-26-142100:0
667 shares0Common StockSEC:0001193125-26-142099:0
769 shares@ US$3.36429.8% of flowCommon StockSEC:0001193125-26-007760:0
1,702 shares@ US$3.36429.1% of flowCommon StockSEC:0001193125-26-007751:0
537 shares@ US$4.3146Common StockSEC:0001193125-25-280481:1
7,862 shares@ US$4.0594Common StockSEC:0001193125-25-280481:2
883 shares@ US$4.0594Common StockSEC:0001193125-25-280481:3
28,597 shares@ US$3.90010.3% of flowCommon StockSEC:0001193125-25-280481:4
3,213 shares@ US$3.90010.0% of flowCommon StockSEC:0001193125-25-280481:5
4,783 shares@ US$4.314612.1% of flowCommon StockSEC:0001193125-25-280481:0
3,247 shares@ US$5.1799Common StockSEC:0001193125-25-274540:1
17,746 shares@ US$4.7467Common StockSEC:0001193125-25-274540:2
1,993 shares@ US$4.7467Common StockSEC:0001193125-25-274540:3
16,633 shares@ US$4.5398Common StockSEC:0001193125-25-274540:4
1,869 shares@ US$4.5398Common StockSEC:0001193125-25-274540:5
28,902 shares@ US$5.179987.9% of flowCommon StockSEC:0001193125-25-274540:0
1,565 shares@ US$8.9170.9% of flowCommon StockSEC:0000950170-25-095682:0
684 shares@ US$8.9170.2% of flowCommon StockSEC:0000950170-25-095681:0
800,000 shares0Common StockSEC:0000950170-25-004167:0
420,000 shares0Common StockSEC:0000950170-25-004166:0
300,000 shares0Common StockSEC:0000950170-24-115597:0
100,000 shares0Common StockSEC:0000950170-24-115594:0
275,000 shares0Common StockSEC:0000950170-24-034350:0
25,000 shares@ US$2.9638100.0% of flowCommon StockSEC:0000950170-23-063137:0
Canonical exit: 8 Feb 2024 (T+90)
25 of 103 declarations
About Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. is a U.S.-listed clinical-stage biotechnology company traded on the NASDAQ under the ticker LYRA. The company is headquartered in Watertown, Massachusetts, United States, and focuses on developing localized, long-acting therapies for chronic inflammatory ear, nose, and throat diseases, with a particular emphasis on chronic rhinosinusitis (CRS). Lyra’s strategy is built around a proprietary bioabsorbable drug-delivery platform designed to place medicine directly at the site of disease through a brief in-office procedure, aiming to provide sustained local therapy and reduce the need for repeated medical treatment or surgery. Its lead product candidates are LYR-210 and LYR-220, both nasal implants designed to deliver mometasone furoate over an extended period.
From an industry perspective, Lyra is a highly focused specialty biotech rather than a broad pipeline company. Its origins are tied to the development of a delivery technology platform aimed at improving treatment precision in sinonasal disorders. That focus gives the company a differentiated position: it targets a large but under-served CRS population, especially patients who continue to suffer symptoms despite standard therapy and may otherwise progress to sinus surgery. In that sense, Lyra sits between conventional drug therapy and procedural intervention, which is a compelling niche if the clinical and commercial case holds up.
Read moreShow less
Lyra’s competitive positioning comes from the combination of local drug delivery, bioresorbable implant design, and office-based administration. These features could be attractive to physicians, patients, and payers if the benefits are durable and the safety profile remains acceptable. At the same time, the company’s value proposition is concentrated in a very limited number of assets, which makes it highly dependent on the success of LYR-210 in clinical development, regulatory review, and eventual commercialization. That concentration raises execution risk, financing risk, and binary event risk typical of development-stage biotechs.
Recent developments have been pivotal. In June 2025, Lyra reported positive results from its ENLIGHTEN 2 Phase 3 trial of LYR-210, a meaningful clinical milestone. However, the company later disclosed in January 2026 that its board approved a suspension of LYR-210 development and a major workforce reduction, signaling a sharp strategic shift. In February 2026, Nasdaq notified Lyra of a delisting determination, underscoring the company’s deteriorating listing and operating profile. These events are important for investors because they show that Lyra’s outlook is no longer defined only by clinical science, but also by capital structure, listing status, and corporate restructuring.
For French-speaking investors, Lyra Therapeutics is best viewed as a highly specialized NASDAQ-listed biotech in the United States, with a potentially differentiated ENT platform but substantial clinical, financial, and market-access risk.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
